Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 221,573,136
  • Shares Outstanding, K 959,025
  • Annual Sales, $ 24,540 M
  • Annual Income, $ 6,194 M
  • 60-Month Beta 0.25
  • Price/Sales 9.13
  • Price/Cash Flow 29.00
  • Price/Book 37.35
Trade LLY with:

Options Overview

Details
  • Implied Volatility 24.95%
  • Historical Volatility 22.98%
  • IV Percentile 12%
  • IV Rank 17.73%
  • IV High 44.72% on 03/12/21
  • IV Low 20.69% on 06/22/21
  • Put/Call Vol Ratio 0.69
  • Today's Volume 4,198
  • Volume Avg (30-Day) 5,356
  • Put/Call OI Ratio 1.02
  • Today's Open Interest 80,313
  • Open Int (30-Day) 73,454

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.97
  • Number of Estimates 4
  • High Estimate 2.03
  • Low Estimate 1.92
  • Prior Year 1.54
  • Growth Rate Est. (year over year) +27.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
228.23 +0.82%
on 09/17/21
274.76 -16.25%
on 08/18/21
-42.61 (-15.62%)
since 08/17/21
3-Month
217.00 +6.04%
on 06/23/21
275.87 -16.59%
on 08/17/21
+7.89 (+3.55%)
since 06/17/21
52-Week
129.21 +78.08%
on 10/30/20
275.87 -16.59%
on 08/17/21
+77.63 (+50.91%)
since 09/17/20

Most Recent Stories

More News
Turner Syndrome Market: by Industry Type, Growth, Share, Size, Key Manufacturers, Revenue, Trends, Growth, Geographical Outlook and Forecast to 2028

Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2028"which delivers a detailed overview of the turner syndrome drug market in terms of market segmentation by type,...

PFE : 43.89 (-1.30%)
NOVN : 8.56 (+1.30%)
BHC : 27.27 (-1.02%)
JNJ : 164.75 (-0.28%)
LLY : 230.10 (-0.41%)
ABT : 126.79 (-0.51%)
MRK : 71.68 (-0.40%)
SAN : 3.58 (-3.24%)
GSK.LN : 1,388.200 (-0.49%)
Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail

FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.

REGN : 651.88 (-0.20%)
GSK : 38.93 (-0.46%)
LLY : 230.10 (-0.41%)
VIR : 54.54 (+3.67%)
AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.

PFE : 43.89 (-1.30%)
LLY : 230.10 (-0.41%)
INCY : 75.99 (+1.27%)
ABBV : 107.73 (-0.32%)
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

MRK : 71.68 (-0.40%)
LLY : 230.10 (-0.41%)
ABBV : 107.73 (-0.32%)
TBPH : 7.11 (+3.64%)
AERI : 12.94 (+4.86%)
RGNX : 45.04 (+0.92%)
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19

/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure...

LLY : 230.10 (-0.41%)
Regeneron, Lilly Get New COVID Drug Deals From Government

Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab...

REGN : 651.88 (-0.20%)
GSK : 38.93 (-0.46%)
RHHBY : 46.0700 (-1.60%)
LLY : 230.10 (-0.41%)
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for EXKIVITY

Thermo Fisher (TMO) gains FDA pre-market approval for Oncomine Dx as companion diagnostic for Takeda's EXKIVITY.

LLY : 230.10 (-0.41%)
TMO : 596.80 (+6.49%)
IDXX : 661.71 (-0.26%)
SMLR : 108.7200 (+1.59%)
Neuroblastoma Drugs Market By Delivery, Type, Systems, End-User 2028

Research Nester published a report titled "- Global Demand Analysis and Opportunity Outlook 2020-2028" which delivers detailed overview of the neuroblastoma drugs market in terms of market segmentation...

CLRB : 1.0100 (+2.01%)
PFE : 43.89 (-1.30%)
LLY : 230.10 (-0.41%)
AZN.LN : 8,063.001 (-0.96%)
TEVA : 8.99 (+0.45%)
BMY : 61.31 (+0.13%)
MGNX : 20.48 (-2.43%)
JNJ : 164.75 (-0.28%)
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval From MHLW

Thermo Fisher's (TMO) Oncomine Dx Target Test has been approved by MHLW as a companion diagnostic for Eli Lilly and Company's selpercatinib.

LLY : 230.10 (-0.41%)
TMO : 596.80 (+6.49%)
IDXX : 661.71 (-0.26%)
SMLR : 108.7200 (+1.59%)
Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for...

LLY : 230.10 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

3rd Resistance Point 233.81
2nd Resistance Point 232.32
1st Resistance Point 231.21
Last Price 230.10
1st Support Level 228.61
2nd Support Level 227.12
3rd Support Level 226.01

See More

52-Week High 275.87
Last Price 230.10
Fibonacci 61.8% 219.85
Fibonacci 50% 202.54
Fibonacci 38.2% 185.23
52-Week Low 129.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar